Natco Pharma Intrinsic Value
Natco Pharma intrinsic value. Natco Pharma (NATCOPHARM) median intrinsic value is ₹1643.90 from 10 valuation models (range ₹247–₹2055), vs current price ₹821.95 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Browse NATCOPHARM financial statements for revenue, profit, balance sheet and cash flow data.
NATCOPHARM Valuation Methods Summary — DCF, Graham Number & P/E
Natco Pharma intrinsic value across 10 models vs current price ₹821.95 — upside/downside and value range per method. Analyse NATCOPHARM promoter holding to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹995.28 | ₹796.22 - ₹1194.34 | +21.1% | EPS: ₹45.24, Sector P/E: 22x |
| Book Value Method | asset | ₹2054.88 | ₹1849.39 - ₹2260.37 | +150.0% | Book Value/Share: ₹2561.39, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1643.90 | ₹1479.51 - ₹1808.29 | +100.0% | Revenue/Share: ₹1132.22, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1643.90 | ₹1479.51 - ₹1808.29 | +100.0% | EBITDA: ₹1240.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹2054.88 | ₹1643.90 - ₹2465.86 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹289.54 | ₹260.59 - ₹318.49 | -64.8% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹698.96 | ₹629.06 - ₹768.86 | -15.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1643.90 | ₹1479.51 - ₹1808.29 | +100.0% | ROE: 8.8%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹1614.69 | ₹1453.22 - ₹1776.16 | +96.4% | EPS: ₹45.24, BVPS: ₹2561.39 |
| Dividend Yield Method | dividend | ₹246.59 | ₹221.93 - ₹271.25 | -70.0% | DPS: ₹5.00, Target Yield: 2.5% |
NATCOPHARM Intrinsic Value vs Market Price — All Valuation Models
Natco Pharma fair value range ₹247–₹2055 vs current market price ₹821.95 across 10 valuation models. For current market price and key ratios, visit Natco Pharma screener.
NATCOPHARM Intrinsic Value Analysis — Undervalued or Overvalued?
Natco Pharma median intrinsic value ₹1643.90, current price ₹821.95 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of NATCOPHARM?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Natco Pharma (NATCOPHARM) is ₹1643.90 (median value). With the current market price of ₹821.95, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹246.59 to ₹2054.88, indicating ₹246.59 - ₹2054.88.
Is NATCOPHARM undervalued or overvalued?
Based on our multi-method analysis, Natco Pharma (NATCOPHARM) appears to be trading below calculated value by approximately 100.0%.
NATCOPHARM Financial Health — Key Ratios vs Industry Benchmarks
Natco Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 8.8% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 27.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.37x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
NATCOPHARM Cash Flow Quality — Operating & Free Cash Flow
Natco Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹1,768 Cr | ₹775 Cr | Positive Free Cash Flow | 7/10 |
| March 2025 | ₹1,697 Cr | ₹979 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹1,212 Cr | ₹699 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹849 Cr | ₹617 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹47 Cr | ₹47 Cr | Positive Free Cash Flow | 8/10 |